Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

There's A Pharma Waiting In The Sky: Lilly In Space

Executive Summary

NASA's orbiting laboratory on the International Space Station has allowed researchers from drug manufacturers like Eli Lilly & Co. to find solutions in space to certain obstacles they've struggled with on Earth, potentially helping the firms get their investigational medicines to the marketplace sooner.

You may also be interested in...



A Life Sciences Fortuitous Opportunity: NASA's Twins Study

While the goal of the yearlong mission aboard the International Space Station (ISS) involving US astronaut Scott Kelly and his Russian counterpart cosmonaut Mikhail Kornienko, who both returned to Earth on March 2, was intended to examine the effects of microgravity on the human body with the aim of reducing the health risks on future crewmembers, NASA serendipitously fell into a fortuitous situation to study spaceflight at the molecular level, potentially providing the life sciences sector a wealth of data – an opportunity that may not come around again for quite some time, if at all.

Pharma's Space Frontier: Come On And Take A Free Ride

Space is waiting for you pharma. So come on and take a free ride – literally.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel